Skip to main content
. 2006 Dec 18;150(3):261–270. doi: 10.1038/sj.bjp.0706980

Table 2.

Effect of β-AR antagonists on relaxation curves of (−)isoprenaline

  WT
 KO
  n −log EC50M P Emax P n −log EC50M P Emax P
(−)-Isoprenaline                    
 Control 13/7 7.31±0.17   39.9±6.3   12/7 6.84±0.1   36.7±3.4  
 CGP20712A (300 nM) 8/4 6.93±0.29 NS 19.6±3.7 <0.02 6/3 7.21±0.06 <0.03 51.3±2.9 <0.02
 ICI118551 (50 nM) 5/3 6.74±0.1 <0.04 28.7±4.2 NS 6/3 6.21±0.09 <0.002 29.7±4.5 NS
 L748337 (100 nM) 4/2 6.62±0.34 NS 33.3±6.3 NS 10/5 6.85±0.07 NS 42.4±4.7 NS
 CGP20712A + ICI118551 8/4 5.24±0.12 <0.0001 12.8±2.1 <0.002 7/4 7.99±0.20H <0.0001 8.2±2.0 <0.0001
            7/4 5.32±0.10L <0.0001 36.0±3.4 <0.0001
 CGP20712A+ICI118551+L748337 3/2 5.10±0.46 <0.0004 25.4±8.8 NS 5/4 5.22±0.25 <0.0001 17.0±7.9 <0.02
                     
BRL37344                    
 Control 3/2 5.18±0.41   8.6±4.5   7/4 8.73±0.35H   6.25±2.5  
            7/4 6.10±0.18L   19.4±3.5  
 L748337 (100 nM)           7/4 6.51±0.45 NS 18.9±4.3 NS
                     
 Control (L-NAME experiments)           6/3 8.75±0.09H   26.9±2.5  
            6/3 6.22±0.38L   64.5±2.8  
 L-NAME (100 μM)           6/3 8.29±0.27H NS 15.8±1.7 <0.04
            6/3 5.74±0.33L NS 39.2±4.0 <0.03

Abbreviation: NS, not significant.

P-values are with respect to the corresponding control in the WT and cav-1KO.

Emax: Maximum relaxation in the presence of the agonist compared with relaxation in the presence of 30 μM SNP.

H

: high-affinity component.

L

: low-affinity component.